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See Article, pages 1361–1367Primary biliary cirrhosis (PBC) is an immune-mediated chronic
progressive inﬂammatory liver disease which affects up to one
in a thousand middle-aged women (with a gender distribution
of female:male of about 10:1) in the Northern hemisphere and
leads, without medical treatment, to the destruction of small
interlobular bile ducts, progressive cholestasis, ﬁbrosis, and cir-
rhosis commonly necessitating liver transplantation. A diagnosis
of PBC is made ‘‘with conﬁdence’’ when biochemical markers of
cholestasis in serum, particularly alkaline phosphatase (AP), are
elevated persistently for more than 6 months in the presence of
serum antimitochondrial antibodies (AMA) and in the absence
of an alternative explanation [1,2]. Compatible histological ﬁnd-
ings conﬁrm the diagnosis and allow staging (1: portal inﬂamma-
tion; 2: periportal inﬂammation; 3: ﬁbrosis; 4: cirrhosis) before
therapeutic intervention, but histological workup is usually not
required to diagnose PBC [1,2].
The pathogenesis of PBC remains elusive [3,4] although
increasing evidence suggests a concomitant role of (i) genetic fac-
tors as supported by sibling studies [5] and genome-wide associ-
ation analyses [6], (ii) exogenous factors as suggested by
immunoreactivity towards infectious agents [7] and by a higher
incidence after exposure to potential environmental toxins
[8,9], and (iii) endogenous factors such as toxic bile salts in indi-
viduals with a defective ‘‘biliary bicarbonate umbrella’’ [10,11].
Today, the post-transcriptional secretagogue, ursodeoxycholic
acid (UDCA) [12], at doses of 13–15 mg/kg/d is recommended as
the standard treatment of PBC both by European [1] and Ameri-
can [2] Clinical Practice Guidelines as it improves serum bio-
chemistry, delays development of liver ﬁbrosis and portal
hypertension, and may normalize life expectancy in up to two
of the three patients treated – a major achievement for patients
with PBC when compared to their fellow sufferers 25 years ago
[13–15]. Liver transplantation is reserved for patients with
advanced disease with signs and symptoms of decompensated
cirrhosis not adequately responding to UDCA treatment [1,2].Journal of Hepatology 20
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in 35–40% of PBC patients who do not adequately respond to
UDCA treatment is a focus of current research efforts. A number
of promising drugs, such as the combined glucocorticoid receptor
(GR)/pregnane X receptor (PXR) agonist, budesonide, the farne-
soid X receptor (FXR) agonist, obeticholic acid (OCA), the peroxi-
some proliferator-activated receptor a (PPARa) agonists, bezaﬁbrate
and fenoﬁbrate, or the C23 UDCA homologue, norUDCA, are under
evaluation as additive treatment options in combination with
UDCA [4].
But how can treatment efﬁcacy of novel agents in an orphan
disease with an expected disease course of one to two decades
effectively be evaluated? During the last 20 years – in the UDCA
era – it has been impossible to organize a therapeutic trial in PBC
which came close to the needs of an ‘‘ideal’’ trial with 1000 or
more patients with PBC treated with UDCA or placebo over a per-
iod of ﬁve or more years in order to ﬁnd a signiﬁcant difference in
transplantation-free survival, the primary endpoint which is
regarded as the golden standard for therapeutic efﬁcacy in
chronic liver diseases. Today, the situation is even more difﬁcult
as it is common sense that any new drug for PBC should be tested
in combination with UDCA against UDCA alone [16]. This scenario
would ask for even larger and longer trials than those needed to
show efﬁcacy of UDCA alone when transplantation-free survival
was chosen as the primary endpoint.
Surrogate markers of prognosis in PBC have been evaluated in
large cohorts of PBC patients already in the 1970s, 1980s, and
1990s. Serum bilirubin was demonstrated to be the single most
potent prognostic marker in PBC [17], but also serum albumin,
age, prothrombin time, and cirrhosis have been unravelled and
cross-validated as valuable surrogate markers to predict progno-
sis mainly of late stage disease. The PBC Mayo risk score is a com-
posite of prognostic surrogate markers and a powerful tool to
predict short-term prognosis of late stage PBC [18]. The purpose
of future trials, however, is to recognize early stage patients who
are in need of combination therapy to hinder progression to cir-
rhosis and death.
Pares and colleagues from Barcelona sought to determine the
long-term prognosis of 192 Spanish patients with PBC of all
stages under UDCA treatment in relation to their biochemical
response to treatment. When they deﬁned an ‘‘adequate response11 vol. 55 j 1178–1180
Table 1. Criteria of ‘‘adequate response to UDCA’’ in PBC.
Criteria “Adequate response to UDCA” Cohort 
(size, 
stage, 
follow-up)
[Ref.]
Barcelona Decrease of serum AP by >40% 
or AP normalization (after 1 year)
n = 192, 
stages 1-4,
mean 6.8 yrs
Death or liver transplantation
Definition of adverse outcome
[13]
Paris I AP ≤3 x ULN, AST ≤2 x ULN, 
and serum bilirubin ≤1 mg/dl (after 1 year)
n = 292, 
stages 1-4,
mean 6.1 yrs
Death or liver transplantation [14]
Rotterdam Normalization of abnormal serum bilirubin 
and/or albumin (after 1 year)
n = 375, 
stages 1-4,
median 9.7 yrs
Death or liver transplantation [15]
Toronto AP <1.67 x ULN (after 2 years) n = 69,
stages 1-3,
median 9.8 yrs
median 7.0 yrs
Progression by ≥1 histological stage [19]
Paris II AP and AST <1.5 x ULN, 
serum bilirubin <1 mg/dl (after 1 year)
n = 167,
stages 1-2
Liver-related death, liver transplantation 
or referral to a transplant unit; ascites, 
variceal bleeding, hepatic encephalopa-
thy, hepatocellular carcinoma; histological 
evidence of cirrhosis
[20]
JOURNAL OF HEPATOLOGYto UDCA’’ after 1 year of treatment by a decrease of serum AP by
>40% or AP normalization (Barcelona criteria) [13], they found that
patients adequately responding to UDCA had a survival similar to
the normal population (Table 1). Corpechot and colleagues from
Paris cross validated the Barcelona criteria in an independent
cohort of 292 French patients with PBC (all stages) and found that
a composite of AP 63  upper limit of normal (ULN), AST
62  ULN, and serum bilirubin 61 mg/dl (Paris I criteria) were
superior to the Barcelona criteria in order to predict normal life
expectancy during long-term follow-up [14]. Kuiper and col-
leagues from the Netherlands cross validated the Barcelona and
Paris I criteria in comparison to their own Rotterdam criteria (nor-
malization of serum bilirubin and/or albumin after 1 year from
elevated levels before start of UDCA treatment) in an indepen-
dent cohort of 375 Dutch PBC patients for a period of 15 years
and found that response to UDCA treatment according to Rotter-
dam criteria was associated with normal survival independent of
the stage of disease before start of treatment [15]. They also con-
ﬁrmed that early stage patients under UDCA treatment had a sur-
vival comparable to the normal population after 15 years. In their
cohort, the prognostic information as provided by the Paris I cri-
teria was superior to that provided by the Barcelona criteria. This
may have in part been due to the severity of disease in the Rot-
terdam cohort which was closer to the more advanced Paris
cohort than the less advanced Barcelona cohort.
Recently, Kumagi and colleagues from Toronto studied a
cohort of 69 patients with PBC with a follow-up liver biopsy
about 10 years after ﬁrst biopsy and start of UDCA treatment
[19]. They found that an AP >1.67  ULN after 2 years of UDCA
treatment, along with ductopenia at ﬁrst biopsy, predicted pro-
gression of disease by at least one stage after 10 years (Table 1).
In the present issue of the Journal, Corpechot and colleagues
from Paris re-evaluated their Paris I criteria in a cohort of 167Journal of Hepatology 2011patients, all with early stage (1 or 2) PBC, and tested different
threshold values for AP, AST, and bilirubin in order to predict
long-term outcome under UDCA treatment [20]. The revised def-
inition of adverse outcomes included liver-related death, liver
transplantation, or referral to a transplant unit, complications of
cirrhosis, such as ascites, variceal bleeding, hepatic encephalopa-
thy or hepatocellular carcinoma, or histological evidence of cir-
rhosis. The results of the present analysis allowed the
conclusion that an AP and AST <1.5  ULN and a normal serum
bilirubin one year after start of UDCA treatment (Paris II crite-
ria) predict outcome free of adverse events and help to identify
those patients with early histological stage who do not need
any treatment in addition to UDCA and thus are not eligible for
future clinical trials [20].
Corpechot et al., cross validated the former Barcelona, Paris I,
Rotterdam and Toronto criteria in their cohort of patients with
early stage PBC and found that the Toronto and Paris I criteria
came closest to the Paris II criteria regarding speciﬁcity, positive
predictive value, and positive likelihood ratio for predicting
adverse outcome. This result was not unexpected for the Paris I
criteria as there was some overlap between the Paris I and II
cohorts. However, this cross validation further underlined the
unique prognostic value of serum AP in early stage PBC as repre-
sented in the Toronto and Paris II cohorts. Thus, serum AP appears
as an useful prognostic marker for prediction of adverse outcome
in early stage PBC and deserves particular attention as a key sur-
rogate inclusion marker for future therapeutic trials.
The recent study of Drs. Corpechot, Chazouilleres, and Poupon
is clearly a step forward in the search for criteria to identify
patients with PBC in need of new therapies. However, as correctly
stated by the authors, the limited number of patients and
particularly of adverse events in this study prevent a deﬁnite
conclusion and ask for extramural cross validation in an indepen-vol. 55 j 1178–1180 1179
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dent large cohort of early stage PBC patients before the Paris II
criteria can be used as a ‘‘selection means’’ for future clinical trials
[20]. An inadequate response to UDCA as deﬁned by the Paris II
criteria also had a low negative predictive value of 13% and only
a moderate sensitivity of 51% for the occurrence of adverse events
[20]. Thus, a considerable percentage of early stage patients
selected by Paris II criteria would undergo additional treatment
without real need, and only every second patient with an adverse
outcome could be identiﬁed beforehand based on the Paris II
criteria. These restrictions need to be kept in mind when the
Paris II criteria are being cross validated in independent cohorts
of early stage PBC patients in the near future. Their prognostic
value in late stages 3–4 disease still remains to be determined.
In summary, the Paris II criteria presented by Corpechot et al.
in the present issue of the Journal appear as a promising selection
tool for patients with early stage PBC in need of novel therapies in
addition to UDCA. Extramural cross validation of Paris II criteria is
urgently awaited.Conﬂict of interest
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